

Methotrexate, vinBLASTine, DOXOrubicin, CISplatin (MVAC) -28 Days Therapy

INDICATIONS FOR USE:

INDICATION	ICD10	Regimen Code	Reimbursement Status
Neoadjuvant treatment of muscle invasive transitional cell carcinoma (TCC) of the urothelium	C67	00338a	Hospital
Adjuvant treatment of muscle invasive TCC of the urothelium	C67	00338b	Hospital
Locally advanced or metastatic TCC of the urothelium	C67	00338c	Hospital

TREATMENT:

The starting dose of the drugs detailed below may be adjusted downward by the prescribing clinician, using their independent medical judgement, to consider each patients individual clinical circumstances.

Neoadjuvant: Treatment is administered as described in treatment table below every 28 days for **3** cycles unless there is disease progression or unacceptable toxicity develops prior to radical cystectomy.

Adjuvant: Treatment is administered as described in treatment table below every 28 days for **4** cycles unless there is disease progression or unacceptable toxicity develops.

Metastatic: Treatment is administered as described in treatment table below for up to **6** cycles or until disease progression or unacceptable toxicity develops.

Facilities to treat anaphylaxis MUST be present when systemic anti cancer therapy (SACT) is administered.

Day	Drug	Dose	Route	Diluent & Rate	Cycle
1, 15, 22	Methotrexate	30mg/m ²	IV Bolus		Every 28 days
2, 15, 22	^a vinBLASTine	3mg/m ²	IV infusion	50ml 0.9% NaCl over 15 mins	Every 28 days
2	^b DOXOrubicin	30mg/m ²	IV Bolus		Every 28 days
2	^c CISplatin	70mg/m ²	IV infusion	500ml 0.9% NaCl over 60 mins	Every 28 days

^avinBLASTine is a neurotoxic chemotherapeutic agent. Refer to NCCP Guidance on the Safe Use of Neurotoxic drugs (including Vinca Alkaloids) in the treatment of cancer. [Link](#)

^bLifetime cumulative dose of DOXOrubicin is 450mg/m²
In establishing the maximal cumulative dose of an anthracycline, consideration should be given to the risk factors outlined below and to the age of the patient.ⁱ

^c **Pre and post hydration therapy required for CISplatin**

See local hospital policy recommendations.

Suggested prehydration for CISplatin therapy:

- Administer 10mmol magnesium sulphate (MgSO₄) (+/-KCl 10-20mmol/L if indicated) in 1000 mL sodium chloride 0.9% over 60 minutes.

Administer CISplatin as described above

Post hydration: Administer 1000 ml 0.9% NaCl over 60mins

Mannitol 10% may be used to as per local policy to induce diuresis, although there is no conclusive evidence that this is required. The routine use of furosemide to increase urine flow is not recommended unless there is evidence of fluid overload .

NCCP Regimen: Methotrexate, vinBLASTine, DOXOrubicin and CISplatin (MVAC)-28day Therapy	Published: 20/06/2016 Review: 08/01/2025	Version number: 4
Tumour Group: Genitourinary NCCP Regimen Code: 00338	ISMO Contributor: Prof Maccon Keane	Page 1 of 7

The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician and is subject to HSE's terms of use available at <http://www.hse.ie/eng/Disclaimer>

This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemoregimens

ELIGIBILITY:

- Indications as above
- ECOG 0-2

EXCLUSIONS:

- Hypersensitivity to methotrexate, vinBLASTine, DOXOrubicin, CISplatin or any of the excipients
- Congestive heart failure (LVEF < 50%) or other significant heart disease
- Moderate/severe renal impairment (creatinine clearance < 60 mL/min)
- Pregnancy and Lactation
- Pre existing neuropathies ≥ grade 2
- Significant hearing impairment/tinnitus

PRESCRIPTIVE AUTHORITY:

The treatment plan must be initiated by a Consultant Medical Oncologist.

TESTS:

Baseline tests:

- FBC, Renal and liver profile
- ECG
- MUGA or ECHO (LVEF > 50% to administer doxorubicin) if >65 years or if clinically indicated.
- Audiology and creatinine clearance if clinically indicated

Regular tests:

- FBC, Renal and liver profile prior to each cycle
- If clinically indicated MUGA scan or ECG
- Repeat FBC and renal profile prior to treatment on day 15 and day 22

Disease monitoring:

Disease monitoring should be in line with the patient's treatment plan and any other test/s as directed by the supervising Consultant.

DOSE MODIFICATIONS:

- Any dose modification should be discussed with a Consultant.

NCCP Regimen: Methotrexate, vinBLASTine, DOXOrubicin and CISplatin (MVAC)-28day Therapy	Published: 20/06/2016 Review: 08/01/2025	Version number: 4
Tumour Group: Genitourinary NCCP Regimen Code: 00338	ISMO Contributor: Prof Maccon Keane	Page 2 of 7

The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician and is subject to HSE's terms of use available at <http://www.hse.ie/eng/Disclaimer>

This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemoregimens

Haematological:

Table 1: Dose modification for haematological toxicity on day of chemotherapy

ANC (x10 ⁹ /L)		Platelets (x10 ⁹ /L)	Dose
≥1.5	and	≥100	100% Dose
<1.5	or	<100	Hold*
Febrile neutropenia or ANC < 0.5 for 5-7 days	or	Thrombocytopenic bleeding or platelets < 25	Hold *then 75% of previous dose
*Do not start a new cycles until ANC ≥1.5 x 10 ⁹ /L and platelets ≥100 x10 ⁹ /L			

Renal and Hepatic Impairment:

Table 2: Dose modifications in renal and hepatic impairment

Drug	Renal Impairment		Hepatic Impairment					
	CrCl (ml/min)	Dose	Bilirubin(micromol/L)		AST (Units)	Dose		
Methotrexate	≥50	100%	<50	and	<180	100%		
	20-50	50%	51-85	or	>180	75%		
	<20	Not recommended. If unavoidable, consider haemodialysis	>85			CI		
	Contraindicated in severe hepatic impairment							
vinBLASTine	No dose reduction necessary		Bilirubin(micromol/L)		AST/ALT(Units)	Dose		
			26-51	or	60-180	50%		
			>51	and	Normal	50%		
			>51	and	>180	Omit		
DOXOrubicin	No dose reduction required. Clinical decision in severe impairment.		Bilirubin (micromol/L)		Dose			
			20-51		50%			
			51-85		25%			
			>85		Omit			
			If AST 2-3 x normal, give 75% dose.					
			If AST >3x ULN, give 50% dose					
CISplatin	CrCl (ml/min)	Dose	No dose reduction necessary					
	≥60	100%						
	45-59	75%						
	<45	Consider CARBOplatin						

Management of adverse events:

Table 3: Dose Modification of MVAC Therapy for Adverse Events

Adverse reactions	Recommended dose modification
Neurotoxicity	
Grade 2 present at start of next cycle	Reduce dose of CISplatin and vinBLASStine by 25% dose.
Grade 3	Discontinue CISplatin and vinBLASStine

SUPPORTIVE CARE:

EMETOGENIC POTENTIAL:

Methotrexate	– Low	(Refer to local policy).
vinBLASStine	– Minimal	(Refer to local policy).
DOXOrubicin	– Moderate	(Refer to local policy).
CISplatin	– High	(Refer to local policy).

Consider increased risk of vinca alkaloid-induced adverse effects due to inhibition of CYP3A4 by aprepitant.

PREMEDICATIONS: None usually required

OTHER SUPPORTIVE CARE:

- Hydration prior and post CISplatin administration (**Reference local policy or see recommendations above**). Patient should be encouraged to drink large quantities of liquids for 24 hours after the CISplatin infusion to ensure adequate urine secretion.
- Prophylactic laxatives may be required to prevent constipation related to the use of vinca alkaloids.

ADVERSE EFFECTS / REGIMEN SPECIFIC COMPLICATIONS:

The adverse effects listed are not exhaustive. Please refer to the relevant Summary of Product Characteristics for full details.

- **Neutropenia:** Fever or other evidence of infection must be assessed promptly and treated appropriately.
- **Pleural effusion or ascites:** Methotrexate should be used with caution in patients with pleural effusions or ascites, as methotrexate may accumulate in third space fluid compartments.
- **Extravasation:** vinBLASStine And DOXOrubicin are vesicants which may cause pain and tissue necrosis if extravasated (**Refer to local extravasation guidelines**).
- **Cardiac Toxicity:** DOXOrubicin is cardiotoxic and must be used with caution, if at all, in patients with severe hypertension or cardiac dysfunction.
- **Hypersensitivity:** Hypersensitivity reactions have been reported with CISplatin.
- **Renal Toxicity:** Nephrotoxicity is common with CISplatin. Strongly encourage oral hydration. If oral hydration is not possible (e.g. excessive nausea), IV hydration is indicated. Avoid nephrotoxic drugs such as aminoglycoside antibiotics where possible. Where treatment with nephrotoxic drugs must be used, monitor renal function.

NCCP Regimen: Methotrexate, vinBLASStine, DOXOrubicin and CISplatin (MVAC)-28day Therapy	Published: 20/06/2016 Review: 08/01/2025	Version number: 4
Tumour Group: Genitourinary NCCP Regimen Code: 00338	ISMO Contributor: Prof Maccon Keane	Page 4 of 7

The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician and is subject to HSE's terms of use available at <http://www.hse.ie/eng/Disclaimer>

This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemoregimens

- **Ototoxicity and sensory neural damage:** These are associated with CISplatin therapy. They should be assessed by history prior to each cycle

DRUG INTERACTIONS:

- NSAIDs may decrease the clearance of methotrexate by decreasing its renal perfusion and tubular secretion thus increasing its toxicity.
- Sulphonamides and penicillins may displace bound methotrexate from plasma protein increasing serum methotrexate levels and its toxicity.
- Concomitant administration of drugs that cause folate deficiency may lead to increased methotrexate toxicity.
- Ciprofloxacin may inhibit renal tubular transport of methotrexate, increasing serum methotrexate levels and its toxicity.
- Probenecid may inhibit renal excretion of methotrexate, increasing serum methotrexate levels and its toxicity.
- Co-administration of CISplatin has been reported to cause higher plasma concentrations of vinBLASTine.
- Erythromycin may increase the toxicity of vinBLASTine.
- Concurrent administration of calcium channel blockers with DOXOrubicin should be avoided as they may decrease the clearance of DOXOrubicin.
- CISplatin may potentiate the nephrotoxic and ototoxic effects of loop diuretics and aminoglycosides so concurrent use should be avoided.
- Consider increased risk of vinca alkaloid-induced adverse effects due to inhibition of CYP3A4 by aprepitant.
- Current drug interaction databases should be consulted for more information.

REFERENCES:

1. Guideline on Muscle-Invasive and Metastatic Bladder Cancer (European Association of Urology guideline): American Society of Clinical Oncology Clinical Practice Guideline Endorsement. J Clin Oncol 2016;34
2. KitumaraH, Tsukamoto T Shibata N. et al. 2014. Randomised phase III study of neoadjuvant chemotherapy with methotrexate, doxorubicin, vinblastine and cisplatin followed by radical cystectomy compared with radical cystectomy alone for muscle-invasive bladder cancer: Japan Clinical Oncology Group study JCOG0209. Ann Oncol Advanced Access March 24, 2014.
3. Grossman et al. Neoadjuvant Chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer NEJM 2003; 349 (9):859-866.
4. Loehrer PJ, Einhorn LH, Elson PJ, et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 1992;10:1066-7
5. Russell SD, Blackwell KL, Lawrence J, et al, Independent adjudication of symptomatic heart failure with the use of doxorubicin and cyclophosphamide followed by trastuzumab adjuvant therapy: a combined review of cardiac data from the National Surgical Adjuvant breast and Bowel Project

NCCP Regimen: Methotrexate, vinBLASTine, DOXOrubicin and CISplatin (MVAC)-28day Therapy	Published: 20/06/2016 Review: 08/01/2025	Version number: 4
Tumour Group: Genitourinary NCCP Regimen Code: 00338	ISMO Contributor: Prof Maccon Keane	Page 5 of 7

The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician and is subject to HSE's terms of use available at <http://www.hse.ie/eng/Disclaimer>

This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemoregimens

- B-31 and the North Central Cancer Treatment Group N9831 clinical trials. J Clin Oncol 2010; 28:3416-3421.
6. Irish Medication Safety Network: Best Practice Guidelines For the Safe Use of Intravenous Potassium in Irish Hospitals Available [here](#)
 7. Nephrotoxicity Associated with CISplatin EviQ ID: 184 v.3
<https://www.eviq.org.au/clinical-resources/side-effect-and-toxicity-management/prophylaxis-and-prevention/184-nephrotoxicity-associated-with-CISplatin>
 8. Portilla D et al. CISplatin nephrotoxicity. UptoDate Accessed Oct 2017
https://www.uptodate.com/contents/CISplatin-nephrotoxicity?source=search_result&search=CISplatin%20hydration&selectedTitle=1~150
 9. Krens S D, Lassche, Jansman G F G A, et al. Dose recommendations for anticancer drugs in patients with renal or hepatic impairment. Lancet Onco/2019; 20:e201-08.
 10. NCCP Classification Document for Systemic Anti-Cancer Therapy (SACT) Induced Nausea and Vomiting. V4 2022 Available at:
<https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/nccp-classification-document-for-systemic-anti-cancer-therapy-sact-induced-nausea-and-vomiting.pdf>
 11. Methotrexate Summary of Product Characteristics. Last updated 05/08/2022 . Accessed Jan 2023 Available at: <https://www.medicines.ie/medicines/methotrexate-1-g-10-ml-injection-32833/spc#tabs>
 12. vinBLASTine Sulfate 1mg/ml Solution for Injection. Last updated: 03/02/2022. Accessed Jan 2023 Available at <https://www.medicines.ie/medicines/vinblastine-sulfate-1-mg-ml-solution-for-injection-or-infusion-34194/spc#tabs>
 13. DOXOrubicin HCl 50mg Powder for Solution for Injection. Summary of Product Characteristics. Last updated: 27/02/2019. Accessed Jan 2023 .Available at https://www.hpra.ie/img/uploaded/swedocuments/LicenseSPC_PA0405-097-002_25012016121153.pdf
 14. Cisplatin 1mg/ml Concentrate for Solution for Infusion. Summary of Product Characteristics. Last updated:06/09/22 . Accessed Jan 2023 . Available at <https://www.medicines.ie/medicines/cisplatin-1-mg-ml-concentrate-for-solution-for-infusion-latex-free-vial-stopper--35271/spc>

Version	Date	Amendment	Approved By
1	20/06/2016		Prof Maccon Keane
2	11/12/2017	Updated with new NCCP regimen format, updated with revised CISplatin hydration regimen recommendations	Prof Maccon Keane
3	08/01/2020	Reviewed. Standardisation of treatment table and renal dose modifications. Update of emetogenic potential	Prof Maccon Keane
4	15/05/2023	Updated CISplatin infusion time. Amended renal impairment table. Updated emetogenic potential and drug interaction section. Removed ATC codes	Prof Maccon Keane

NCCP Regimen: Methotrexate, vinBLASTine, DOXOrubicin and CISplatin (MVAC)-28day Therapy	Published: 20/06/2016 Review: 08/01/2025	Version number: 4
Tumour Group: Genitourinary NCCP Regimen Code: 00338	ISMO Contributor: Prof Maccon Keane	Page 6 of 7

The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician and is subject to HSE's terms of use available at <http://www.hse.ie/eng/Disclaimer>

This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemoregimens

Comments and feedback welcome at oncologydrugs@cancercontrol.ie.

ⁱ Cardiotoxicity is a risk associated with anthracycline therapy that may be manifested by early (acute) or late (delayed) effects.

Risk factors for developing anthracycline-induced cardiotoxicity include:

- high cumulative dose, previous therapy with other anthracyclines or anthracenediones
- prior or concomitant radiotherapy to the mediastinal/pericardial area
- pre-existing heart disease
- concomitant use of other potentially cardiotoxic drugs

In establishing the maximal cumulative dose of an anthracycline, consideration should be given to the risk factors above and to the age of the patient.

NCCP Regimen: Methotrexate, vinBLASTine, DOXOrubicin and CISplatin (MVAC)-28day Therapy	Published: 20/06/2016 Review: 08/01/2025	Version number: 4
Tumour Group: Genitourinary NCCP Regimen Code: 00338	ISMO Contributor: Prof Maccon Keane	Page 7 of 7
The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician and is subject to HSE's terms of use available at http://www.hse.ie/eng/Disclaimer <i>This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemoregimens</i>		